58 results about "C-Met inhibitor" patented technology

The present invention relates to compounds and methods use as inhibitors of c-Met. Certain compounds of the subject invention have the following structural formula (I). Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

The present invention provides a compound of Formula I

or a pharmaceutically acceptable salt form thereof, wherein A, L¹, R¹, R², R³, R⁴, R⁵, R⁶, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

The invention discloses a pyridino five-membered heterocyclic derivative or a pharmaceutically acceptable salt of the pyridino five-membered heterocyclic derivative, a structure of which is shown in general formula I. The invention also relates to a preparation method and applications of the pyridino five-membered heterocyclic derivative or the pharmaceutically acceptable salt of the pyridino five-membered heterocyclic derivative in the preparation of drugs used as a c-Met inhibitor.

The present invention is directed to methods of administering foretinib or pharmaceutically acceptable salts or solvates thereof a c-Met inhibitor to a patient in need thereof comprising:

• • determining whether said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene; and
  • if said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene, administering to said patient a pharmaceutical composition comprising foretinib or a pharmaceutically acceptable salt thereof.

A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.

The invention relates to a pyrazolo[1,5-a]miazine compound and its preparation method and medical use. The invention relates to the preparation method of the pyrazolo[1,5-a]miazine compound shown in the general formula (I) and its salt, a pharmaceutical composition containing the pyrazolo[1,5-a]miazine compound or its medicinal salt, the use of the pyrazolo[1,5-a]miazine compound or the pharmaceutical composition in the medicine field and especially as a receptor tyrosine kinase inhibitor and a c-Met inhibitor, and the use of the pyrazolo[1,5-a]miazine compound or the pharmaceutical composition in preparation of drugs for preventing and/or treating c-Met abnormality-related diseases.

The invention belongs to the field of pharmaceutical chemistry, and particularly relates to pyridazinone compounds as shown in general formula I or isomers thereof or pharmaceutically acceptable salt, ester prodrug or solvate thereof, a preparation method thereof, a medicinal composition and application thereof in preparation of a tyrosine kinase inhibitor (especially c-Met inhibitor). The compounds or the medicinal composition thereof serving as a tyrosine kinase inhibitor (especially c-Met inhibitor) can be used for preventing and/or treating neoplastic diseases related to c-Met abnormality.

A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.

The invention relates to the technical field of cancer treatment methods, and in particular relates to a method for treating cancer by the combined application of a c-MET inhibitor and sodium butyrate. The method comprises the step of administrating a drug to a cancer patient through a sodium butyrate preparation and the c-MET inhibitor simultaneously. According to the method for treating the cancer by the combined application of the c-MET inhibitor and sodium butyrate, the growth of a tumor can be effectively inhibited, and the number of tumor stem cells is effectively decreased; moreover, the transplantation efficiency of cancer cells is effectively inhibited, the recurrence rate of the cancer is greatly reduced, and the method is easy to use and popularize.

The invention relates to a quinoline compound which is used as a c-Met depressant and is expressed by the general formula (I) below, a pharmaceutically acceptable salt or pharmaceutically acceptable solvate and a preparation method of the compound, a medicament combination containing the compound and application of the compounds in the preparation of medicaments for preventing or treating diseases relevant to abnormal cell proliferation, morphological change and hyperkinesia with respect to hepatocyte growth factor receptors (HGFR) in an organism as well as diseases relevant to angiogenesis or cancerometastasis, especially medicaments for treating or preventing growth and metastasis of tumors.

The present invention provides methods for preventing retinal microvasculature inflammation in patients with diabetes who are highly susceptible to developing diabetic retinopathy and/or diabetic macular edema. The methods comprise inhibiting C-met signaling pathway by administering a C-met inhibitor alone or in combination with anti-VEGF or steroid medications to diabetic patients. The methods thus provide a surprisingly effective prophylaxis and/or treatment for diabetic retinopathy and/or diabetic macular edema.

The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) atleast one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.